DE60108241D1 - Felabamat-derivate zur behandlung von neuropathischem schmerz - Google Patents
Felabamat-derivate zur behandlung von neuropathischem schmerzInfo
- Publication number
- DE60108241D1 DE60108241D1 DE60108241T DE60108241T DE60108241D1 DE 60108241 D1 DE60108241 D1 DE 60108241D1 DE 60108241 T DE60108241 T DE 60108241T DE 60108241 T DE60108241 T DE 60108241T DE 60108241 D1 DE60108241 D1 DE 60108241D1
- Authority
- DE
- Germany
- Prior art keywords
- neuropathic pain
- derivatives
- felabamate
- treatment
- glaucoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20214500P | 2000-05-05 | 2000-05-05 | |
US202145P | 2000-05-05 | ||
PCT/US2001/014594 WO2001085149A2 (en) | 2000-05-05 | 2001-05-04 | Felbamate derived compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60108241D1 true DE60108241D1 (de) | 2005-02-10 |
DE60108241T2 DE60108241T2 (de) | 2005-05-25 |
Family
ID=22748666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60108241T Expired - Fee Related DE60108241T2 (de) | 2000-05-05 | 2001-05-04 | Felabamat-derivate zur behandlung von neuropathischem schmerz |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1282414B1 (de) |
JP (1) | JP2003532672A (de) |
AT (1) | ATE286390T1 (de) |
AU (2) | AU2001261219B2 (de) |
CA (1) | CA2407697A1 (de) |
DE (1) | DE60108241T2 (de) |
ES (1) | ES2231495T3 (de) |
MX (1) | MXPA02010837A (de) |
NZ (1) | NZ522249A (de) |
PT (1) | PT1282414E (de) |
WO (1) | WO2001085149A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10136842A1 (de) * | 2001-07-23 | 2003-02-13 | Schering Ag | GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität |
WO2009129181A1 (en) * | 2008-04-14 | 2009-10-22 | Concert Pharmaceuticals Inc. | Propanediol-dicarbamate derivatives |
FR2948660B1 (fr) * | 2009-07-30 | 2011-08-19 | Oroxcell | Derives de 2-amino-2-phenyl-alkanol, leur preparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
MXPA01007968A (es) * | 1999-02-09 | 2003-07-14 | Univ Virginia | Compuestos derivados del felbamato. |
-
2001
- 2001-05-04 WO PCT/US2001/014594 patent/WO2001085149A2/en active IP Right Grant
- 2001-05-04 AU AU2001261219A patent/AU2001261219B2/en not_active Ceased
- 2001-05-04 JP JP2001581803A patent/JP2003532672A/ja not_active Withdrawn
- 2001-05-04 EP EP01935095A patent/EP1282414B1/de not_active Expired - Lifetime
- 2001-05-04 ES ES01935095T patent/ES2231495T3/es not_active Expired - Lifetime
- 2001-05-04 PT PT01935095T patent/PT1282414E/pt unknown
- 2001-05-04 CA CA002407697A patent/CA2407697A1/en not_active Abandoned
- 2001-05-04 NZ NZ522249A patent/NZ522249A/en unknown
- 2001-05-04 MX MXPA02010837A patent/MXPA02010837A/es active IP Right Grant
- 2001-05-04 AU AU6121901A patent/AU6121901A/xx active Pending
- 2001-05-04 DE DE60108241T patent/DE60108241T2/de not_active Expired - Fee Related
- 2001-05-04 AT AT01935095T patent/ATE286390T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2001261219B2 (en) | 2005-08-25 |
PT1282414E (pt) | 2005-04-29 |
JP2003532672A (ja) | 2003-11-05 |
WO2001085149A3 (en) | 2002-05-30 |
MXPA02010837A (es) | 2004-02-26 |
AU6121901A (en) | 2001-11-20 |
ES2231495T3 (es) | 2005-05-16 |
CA2407697A1 (en) | 2001-11-15 |
ATE286390T1 (de) | 2005-01-15 |
EP1282414A2 (de) | 2003-02-12 |
DE60108241T2 (de) | 2005-05-25 |
EP1282414B1 (de) | 2005-01-05 |
WO2001085149A2 (en) | 2001-11-15 |
NZ522249A (en) | 2004-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60101265D1 (de) | Behandlung von augenschmerzen | |
ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
DE60141636D1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
DE60231107D1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
DE60108241D1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
ATE302009T1 (de) | Ubichinon qn zur behandlung von migräneschmerzen | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
DE602005013805D1 (de) | Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen | |
DE60124791D1 (de) | S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen. | |
TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders | |
SE0003126D0 (sv) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |